Coherus Oncology (NASDAQ:CHRS) Rating Increased to Strong-Buy at Guggenheim

Guggenheim upgraded shares of Coherus Oncology (NASDAQ:CHRS) to a strong-buy rating in a report released on Monday morning,Zacks.com reports.

A number of other research firms also recently weighed in on CHRS. Weiss Ratings raised shares of Coherus Oncology from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, April 22nd. Wall Street Zen upgraded shares of Coherus Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, Oppenheimer initiated coverage on shares of Coherus Oncology in a research report on Thursday, January 22nd. They issued an “outperform” rating and a $10.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $8.67.

Coherus Oncology Trading Up 11.4%

NASDAQ:CHRS opened at $1.95 on Monday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.45 and a current ratio of 1.47. The firm has a market cap of $300.73 million, a price-to-earnings ratio of 1.34 and a beta of 1.01. Coherus Oncology has a 52 week low of $0.71 and a 52 week high of $2.62. The firm has a 50-day moving average price of $1.74 and a two-hundred day moving average price of $1.63.

Coherus Oncology (NASDAQ:CHRS) last posted its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.01). The firm had revenue of $12.31 million during the quarter, compared to analysts’ expectations of $14.22 million. Coherus Oncology had a net margin of 398.42% and a negative return on equity of 860.29%. On average, equities analysts expect that Coherus Oncology will post -0.93 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Coherus Oncology

A number of hedge funds have recently modified their holdings of the company. Jane Street Group LLC bought a new stake in shares of Coherus Oncology during the 2nd quarter valued at about $46,000. BNP Paribas Financial Markets boosted its stake in shares of Coherus Oncology by 108.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 13,832 shares in the last quarter. Corient Private Wealth LLC boosted its stake in shares of Coherus Oncology by 20.0% during the 2nd quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 10,000 shares in the last quarter. Blair William & Co. IL bought a new stake in shares of Coherus Oncology during the 4th quarter valued at about $27,000. Finally, Quarry LP bought a new stake in shares of Coherus Oncology during the 3rd quarter valued at about $26,000. Hedge funds and other institutional investors own 72.82% of the company’s stock.

Coherus Oncology Company Profile

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.